Back to Peptides
Weight Loss
Semaglutide
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. By mimicking the incretin hormone GLP-1, research has explored its effects on slowing gastric emptying, enhancing satiety signaling, and improving glycemic control. It is among the most extensively studied peptides for metabolic and body-weight outcomes, with a once-weekly dosing profile enabled by its extended half-life.
Weight LossMetabolicGLP-1SC/Oral
Research Benefits
Appetite and satiety regulation documented in large human trials
Glucose control and HbA1c reduction well characterized
Significant body-weight reduction observed in clinical studies
Cardiometabolic markers under continued investigation
Axo's Research Digest
An AI-generated, plain-English overview of what the research explores for Semaglutide — and how mature that evidence is.